# Supplementary text and figures for

*"RADAR: Annotation and prioritization of variants in the posttranscriptional regulome for RNA-binding proteins"* 

### **Table of Contents**

| 1 I        | Defining the RBP regulome using eCLIP data3                     |  |  |  |  |
|------------|---|--|--|--|--|
| 1.1        | 1.1 Functional Annotation of RBPs                               |  |  |  |  |
| 1.2        | 1.2 Functional Annotation of RBP binding sites                  |  |  |  |  |
| 1.3        | Inference of cross-population conservation of RBP binding sites |  |  |  |  |
| Inf        | erence of cross-species conservation of RBP binding sites       |  |  |  |  |
| 1.4        | Inference of structure conservations                            |  |  |  |  |
| 2 I        | RBP binding network analysis7                                   |  |  |  |  |
| 2.1        | RBP co-binding analysis7  |  |  |  |  |
| 2.2        | RBP network hub analysis  |  |  |  |  |
| 3 1        | Motif analysis  |  |  |  |  |
| 3.1        | Motifs from RNA Bind-n-Seq experiments10                        |  |  |  |  |
| 3.2        | Motifs from de novo discovery12                                 |  |  |  |  |
| 3.3        | Motif disruption calculation using MotifTools13                 |  |  |  |  |
| 4 I        | RBP-gene association by RBP KD experiments13                    |  |  |  |  |
| 5 I        | Highlighting key regulators through expression profiles         |  |  |  |  |
| 6          | Applying RADAR to pathological germline variants                |  |  |  |  |
| 7          | Applying RADAR to somatic variants in cancer15                  |  |  |  |  |
| 8          | Comparison of RADAR to other methods17                          |  |  |  |  |
| 9 I<br>9.1 | Using cell type specific information as validation              |  |  |  |  |
|            | pressed genes in HepG2 and K56217                               |  |  |  |  |
| 10         | Downloading and Using the RADAR software19                      |  |  |  |  |
| Refe       | rences  |  |  |  |  |

# List of supplementary figures

| Figure S 1 Annotation summary of RBPs  | 3 |
|--|---|
| Figure S 2. Background Rare variant percentage vs. GC  | 5 |
| Figure S 3. Rare variant enrichment after GC correction in coding and noncoding regions            |   |
| respectively. The dashed blue/red line is the genome average without GC correction for             |   |
| coding and noncoding regions, and the solid blue/red line is the background after GC               |   |
| correction. Blue/Red star on top of each bar indicate significantly enriched in rare variants      |   |
| after GC correction in one-sided binominal test against the coding/noncoding average               | 6 |
| Figure S 4. Increased cross-population conservation after added Evofold feature to RBP peaks       | 7 |
| Figure S 5. Co-binding analysis of RBPs  |   |
| Figure S 6. Distribution of binding RBP numbers  | 9 |
| Figure S 7. Adjusted rare variant percentage vs. number of RBPs binding in coding regions.         |   |
| Regions with top 5% and 1% of RBPs binding are defined as the hot and ultra-hot regions.           |   |
| Figure S 8. Adjusted rare variant percentage vs. number of RBPs binding in noncoding regions.      |   |
| Regions with top 5% and 1% of RBPs binding are defined as the hot and ultra-hot regions.           |   |
|  |   |
| Figure S 9. Schematic of highlighting variants that breaks gene-RBP association from RBP knockdown |   |
| experiments1   |   |
| Figure S 10. Baseline RADAR scores of HGMD vs. all 1kG variants                                    |   |
| Figure S 11. Baseline RADAR score in somatic variants1   |   |
| Figure S 12. Highlighted breast cancer somatic variants in 3'UTR region                            |   |
| Figure S 13. RADAR score comparison in tissue-specific and commonly expressed genes by             |   |
| separating K562 and HepG2 data1  |   |
| Figure S 14 RADAR score comparison in liver cancer specific and common tumor driver genes          |   |
| by separating K562 and HepG2 data1   |   |
| Figure S 15. Details about RADAR scoring system1   | 9 |

# List of tables

| Table S 1 Specific RBPs and their functions                            |    |
|--|----|
| Table S 2 RBP binding peaks within annotated regions                   |    |
| Table S 3 List of RBPs that have both eCLIP and Bind-n-Seq experiments | 10 |
| Table S 4 Comparison of RADAR to Funseq2                               | 17 |


## 1 Defining the RBP regulome using eCLIP data

### 1.1 Functional Annotation of RBPs

eCLIP is an enhanced version of the crosslinking and immunoprecipitation (CLIP) assay, and is used to identify the binding sites of RNA binding proteins (RBPs). We collected all available eCLIP experiments from the ENCODE data portal (encodeprojects.org). There were 178 experiments from K562 and 140 experiments from HepG2, totaling 318 eCLIP experiments from all available ENCODE cell lines (released and processed by July 2017).

These experiments targeted 112 unique RBP profiles. eCLIP data was processed by ENCODE 3 uniform data processing pipeline. The eCLIP peak calling method and processing pipeline were developed by Gene Yeo's lab at the University of California, San Diego (https://github.com/YeoLab/clipper, CLIP-seq cluster-identification algorithm[1]). For each peak, the enrichment significance was calculated against a paired input, and we filtered those peaks with a flag of 1000, which are considered to be the statistically significant peaks.

We summarized the list of available RBPs in Table S 1 (in separate data package) and provided detailed annotation as we can. We also summarized different categories of RBPs as well as the relative size of the RBP regulome in Figure S 1.





Below is a table categorizing each RBP by their function, many of which are splicing related. We also include a downloadable link on our website of eCLIP data annotated by each RBPs specific function, which can easily be filtered for splicing related RBPs, and found at <a href="http://radar.gersteinlab.org/splicing.zip">http://radar.gersteinlab.org/splicing.zip</a>.



| Category               | RBPs  |
|------------------------|---|
| RNA Binding            | DDX3X, DDX59, DGCR8, DROSHA, EWSR1, HNRNPA1, HNRNPC, HNRNPK, HNRNPM, HNRNPU,<br>HNRNPUL1, IGF2BP3, ILF3, KHDRBS1, NONO, NPM1, PCBP2, PRPF8, PTBP1, RBFOX2, RBM15,<br>RBM22, SAFB2, SF3A3, SRSF7, SRSF9, TAF15, TARDBP, TNRC6A, U2AF1, U2AF2, AARS, AUH,<br>CPSF6, CSTF2, CSTF2T, DDX24, DDX42, DDX55, DDX6, DHX30, DKC1, EIF4G2, FAM120A,<br>FASTKD2, FMR1, FUBP3, FXR1, FXR2, GEMIN5, GRSF1, IGF2BP1, IGF2BP2, KHSRP, LARP4,<br>LARP7, LIN28B, LSM11, MTPAP, NOL12, NSUN2, PPIL4, PUM2, PUS1, QKI, RBM27, RPS11, RPS5,<br>SERBP1, SF3B4, SFPQ, SLBP, SLTM, SMNDC1, SRSF1, SUGP2, SUPV3L1, TIA1, TRA2A, TROVE2,<br>UPF1, XPO5, ZRANB2 |
| tRNA Binding           | AARS, NSUN2, XPO5   |
| tRNA Splicing          | CSTF2   |
| Pre mRNA<br>Splicing   | GTF2F1, HNRNPA1, HNRNPC, HNRNPK, HNRNPM, HNRNPU, HNRNPUL1, NONO, PCBP2, PRPF8, PTBP1, RBM15, RBM22, SF3A3, SRSF7, SRSF9, U2AF1, U2AF2, BUD13, CDC40, CSTF2, EFTUD2, GEMIN5, GPKOW, NCBP2, SF3B1, SF3B4, SRSF1, TRA2A  |
| Splicing<br>Regulation | RBFOX2  |
| Polyadenylation        | CPSF6, CSTF2, GRSF1, MTPAP  |
| mRNA Stability         | FMR1, KHSRP, PUM2, SERBP1   |
| rRNA<br>Processing     | DKC1, RPS11, RPS5, SBDS, XRN2   |
| Ribosome<br>Structure  | RPS11, RPS5   |
| RNA Editing            | DKC1, PUS1  |

### 1.2 Functional Annotation of RBP binding sites

From the raw peaks from ENCODE, we further removed the ones overlapped with either blacklist regions from ENCODE (<u>https://www.encodeproject.org/annotations/ENCSR636HFF/</u>, select hg19) or gap regions like Telomere and Centromere from ucsc (ftp://<u>hgdownload.cse.ucsc.edu/goldenPath/hg19/database/gap.txt.gz</u>). In total, over 99% of the binding locations are preserved after blacklist removal.

We further tried to annotate these peak regions by dividing them into different annotation categories from Gencode V19. Specifically, we extracted 7 different annotation categories, including coding exons, 3'UTR, 5'UTR, 3'UTR extended (1000bp downstream), 5'UTR extended (1000bp upstream), nearby intron (up to 100bp to the exon/intron junctions), and deep introns. For any region that might overlap two annotation categories, we only preserve one in the order mentioned above. The raw number of nucleotides in each annotation category is given in Table S 2.

Table S 2 RBP binding peaks within annotated regions


| Annotation Type | Nucleotides |
|-----------------|-------------|
| Coding Exon     | 156069      |

| 3' UTR          | 65447  |
|-----------------|--------|
| 5' UTR          | 28339  |
| 3' UTR extended | 39985  |
| 5' UTR extended | 45036  |
| Nearby Intron   | 102892 |
| Deep Intron     | 312424 |

#### 1.3 Inference of cross-population conservation of RBP binding sites

We tried to infer the cross-population conservation level of the RBP binding sites from polymorphism data in large sequencing cohorts like the 1,000 Genomes Project. Specifically, for each RBP we divided all the binding peaks into coding and noncoding regions separately and then calculated the number of common  $(n_c)$  and rare variants  $(n_r)$  in these two categories. Then a one-sided binomial test of  $n_c$ ,  $n_r$ , vs. the genome background f was calculated to evaluate the enrichment of rare variants.


However, in our analysis we found that GC content might be a potential bias in such calculation. As in Figure S 2, the background rare variant percentage f demonstrates noticeable changes with GC percentage. One possible explanation is that GC content usually affects read coverage in high-throughput sequencing experiments, which is a sensitive parameter in the downstream variant calling process. Therefore, to remove such bias, we calculated the GC adjusted background rare variant percentage by dividing the coding/noncoding regions into 500bp bins, and grouping these bins at GC resolution of 0.02. For each RBP, when calculating the background, we only select the bins with closest GC percentage. The comparison of foreground and background rare variant percentage for every RBP in coding and noncoding regions are given in Figure S 3.





For some RBPs, if there are no coding/noncoding rare/common variants in their binding sites, the *f* value for binomial test will be missing. We provided the full raw calculation of GC corrected rare variant enrichment for each RBP in Table S3.

Figure S 3. Rare variant enrichment after GC correction in coding and noncoding regions respectively. The dashed blue/red line is the genome average without GC correction for coding and noncoding regions, and the solid blue/red line is the background after GC correction. Blue/Red star on top of each bar indicate significantly enriched in rare variants after GC correction in one-sided binominal test against the coding/noncoding average.



#### Inference of cross-species conservation of RBP binding sites

PhastCons conservation scores were downloaded from UCSC genome browser. For each annotation category (coding exons, 3'UTR, 5'UTR, nearby introns), we separate the annotation into regions covered by RBP peak and those not covered. After deduplication and merging of the bed files, we then calculated the average PhastCons score in each region using bigWigAverageOverBed (downloaded from UCSC genome browser). Then the boxplots of peak vs. nonpeak regions were given in Figure S 2 in the main manuscript.


In addition the GERP score sigmoid transformation is given as the equation below:

$$S_{GERP} = 0.62 \times \frac{1}{1 + e^{-40(GERP - 1.85)}}$$
(5)

#### 1.4 Inference of structure conservations

We downloaded the Evofold bed files for hg19 from UCSC Genome Browser and used it as a feature for our analysis. Specifically, we found that after requiring that any RBP peaks should also be with conserved structure in Evofold, these binding sites significantly increases its population-level conservations (as shown in Figure S 4).

#### Figure S 4. Increased cross-population conservation after added Evofold feature to RBP peaks




### 2 RBP binding network analysis

We also investigated the RBP binding events interactions from two aspects: co-binding analysis and RBP binding hub analysis. Details are given in the following sections.

#### 2.1 <u>RBP co-binding analysis</u>

We defined the co-binding percent of each RBP pair by the ratio of overlapping nucleotides over the union of nucleotides in their binding peaks. Then we constructed a co-binding percentage matrix for all RBPs to measure their co-binding status. Then, we performed a hierarchical clustering of this matrix using the pvrect function from the pvclust package in R with an alpha value of 0.02 to identify the co-binding pairs. The resulting clusters of RBPs with significance were found to follow patterns of functional co-binding found in literature and results are given in Figure S 5.




Using a significance level threshold of 0.05, we found several pairs of well-known regulatory partners with different binding preferences. For example, the famous heterogeneous nuclear ribonucleoprotein (hnRNP) family protein HNRNPU and its paralog HNRNPUL1 were found to bind together in the nearby intron region, probably regulating the pre-mRNA splicing process[2]. F3A3 and SF3B4, which encode two units of splicing factor 3a protein, were also found to co-bind in the nearby intron region in our data[3, 4]. The SR family protein U2AF1 and U2AF2 are found to co-bind near the intron/exon junctions to jointly control splicing events[4, 5]. Two cleavage stimulation factor (CSTF) complex proteins, CSTF2 and CSTF2T, were found to bind near the 3' UTR, and were reported to be associated with 3' end cleavage and polyadenylation of pre-mRNAs. Consistent with previous report, three functional similar genes FMR1, FXR1, and FXR2 were found to co-express, and shuttle between the nucleus and cytoplasm and associate with polyribosomes, predominantly with the 60S ribosomal subunit[6, 7]. The discovery of the co-binding of such functional relevant proteins at various regions indicates the high quality of our regulome.

#### 2.2 **RBP network hub analysis**

We also inferred the RBP binding hubs and hypothesized that they are under higher negative selection since once mutated, there is a higher chance to alter RBP regulations. Specifically, we calculated the number of RBPs that bind to each nucleotide and the distribution is given in Figure S 6. As expected, due to the specificity of RBP binding events, the majority (over 60%) of the RBP regulome was surrounded by only one RBP.





We then calculated the enrichment of rare variants for regions with at least 1, 2, 3, ..., 112 RBPs. We corrected the GC bias in a similar way to section 1.3. As expected, as the number of RBPs increased, we observed an obvious trend of enrichment of rare variants (Figure S 7 and Figure S 8). For instance, in the noncoding region, around 5% of the regulome is surrounded with at least 5 RBPs, and they exhibited 3% more rare variants compared to the whole genome. For regions that are surrounded by at least 10 RBPs, which are around 1% of the whole regulome, we observed up to 12% more rare variants (Figure S 8). This observation significantly supports our hypothesis that the RNA regulome hubs are under stronger purifying selection, and should be given higher priority when evaluating the functional impacts of mutations.





Figure S 7. Adjusted rare variant percentage vs. number of RBPs binding in coding regions. Regions with top 5% and 1% of RBPs binding are defined as the hot and ultra-hot regions.

Figure S 8. Adjusted rare variant percentage vs. number of RBPs binding in noncoding regions. Regions with top 5% and 1% of RBPs binding are defined as the hot and ultra-hot regions.



### 3 Motif analysis

In our RADAR framework, we incorporated two sources of motifs: (1) motifs from RNA Bind-n-Seq experiments[8]; (2) *de novo* discoveries from RBP peaks by DREME [9]. For each variant, we used the changes of PWM scores to quantify the binding affinity alterations. If one variant breaks more than one PWM, RADAR will choose the maximum score for it.

#### 3.1 Motifs from RNA Bind-n-Seq experiments

It has been reported that many of the RBPs' binding events *in vivo* can be captured by binding preferences *in vitro*. Hence, we utilized an in vitro RNA binding assay, RNA Bind-N-Seq[8] to characterize sequence and structural specificities of RBPs. We used RBNS motifs from 78 human RBPs to prioritize germline and somatic variants that could potentially disrupt an RNA-binding domain.

Briefly, we called on RBNS motifs based on an enrichment Z-score cutoff of 3. Some RBPs had up to four motifs, which ranged from 5-mer to 9-mers. In total, there are 17 RBPs overlapped with eCLIP RBPs, which are listed in Table S 3 below. We treated all RBNS motifs independently from eCLIP-based *de novo* motifs.

#### Table S 3 List of RBPs that have both eCLIP and Bind-n-Seq experiments

| RBP Name | RBNS motif |
|----------|------------|
|----------|------------|

| 1 | EIF4G2  |  |
|---|---------|--|
| 2 | EWSR1   |  |
| 3 | FUBP3   |  |
| 4 | HNRNPC  |  |
| 5 | HNRNPK  |  |
| 6 | IGF2BP1 |  |
| 7 | IGF2BP2 |  |
| 8 | KHSRP   |  |
| 9 | PCBP2   |  |

| 10 | RBFOX2 |  |
|----|--------|--|
| 11 | RBM22  |  |
| 12 | SFPQ   |  |
| 13 | SRSF9  |  |
| 14 | TAF15  |  |
| 15 | TARDBP |  |
| 16 | TIA1   |  |
| 17 | TRA2A  |  |

### 3.2 Motifs from de novo discovery

We collected the binding peaks for each RBP after blacklist removal. For any peak that is less than 150 bp in length, we extended it to 150 bp from both sides. For those longer than 150bp, we kept the original peak length. We then extracted sequence information from hg19 and

performed *de novo* motif discovery DREME[9] with default settings (Version 4.12.0, http://meme-suite.org/tools/dreme).

#### 3.3 Motif disruption calculation using MotifTools

We used D-score defined in MotifTools (<u>https://github.com/hoondy/MotifTools</u>) to evaluate the binding affinity alterations introduced by a variant. We only considered positive D-scores, which denote a variant that decreases the likelihood that a protein will bind the motif (motifbreak). For variants that affect multiple RBP binding profiles, we used the max score over all D-scores.

### 4 RBP-gene association by RBP KD experiments

RNA-seq expression profiling before and after shRNA mediated RBP depletion from ENCODE can help infer the gene expression changes introduced by RBP knockdown. Variants with disruptive effect on RBP binding may affect or even completely remove RBP binding and hence affect gene expressions in a similar way. A schematic of our procedure is given in Figure S 9.

Specifically, we first collected 472 shRNA RNA-seq experiments (supplementary table S5) and extracted the differentially expressed genes (supplementary table S6) from such experiments. For example, in Figure S 9, we define the G1-RBP2 association from the RBP knockdown experiment. Then within the extended G1 region, we extracted all motif breaking variant effect for all possible RBPs (within peaks). If any variant breaks RBPs that has an association with G1, we give it an extra credit in our baseline score.




Figure S 9. Schematic of highlighting variants that breaks gene-RBP association from RBP knockdown experiments.

## 5 Highlighting key regulators through expression profiles

In order to detect the key RBP regulators that drive the disease-specific gene expression patterns, we constructed RBP regulatory networks and incorporated gene expression profiles to find RBPs that are associated with expression changes in patient cohorts.

Specifically, we first downloaded the full set of TCGA expression profiles for 24 cancer types. In order to get a robust differential expression analysis, we excluded 6 cancer types that have less than 10 normal expression profiles. For each cancer type, both tumor and normal expression were given to DESeq2[10] to identify tumor-specific gene differential expression status.

Then we tried to set up RBP regulatory network directly from the RBP peaks. We used the full set of protein coding genes in Gencode v19, and then extracted their 3'UTR regions. For any protein coding gene, a RBP is supposed to regulate this gene if this RBP has a binding peak intersecting the 3'UTR region.


We inferred the regulation power of each RBP by through a regression approach of the above differential expression status and RBP network connectivity. We used the absolute value of regression coefficient as the aggregated RBP regulation power. The full table of regulation powers in all 19 cancer types were given in Supplementary Table S7. Interestingly, we found that for the RBPs with larger regulation power are those tends to be known to associated with cancer, as listed in Supplementary Table S8.

For RBPs with high regulation powers, we also performed a patient-wise regulation power inference, where the differential expression is determined as the individual expression fold change. Then, we tried to use such individual regulatory power to predict disease prognosis. We downloaded the patient survival data from TCGA and performed survival analysis using the survival package in R (version 2.4.1-3).

### 6 Applying RADAR to pathological germline variants

HGMD variants (version 2015) were used in our analysis. For Figure 6, the signal tracks for the eCLIP experiments were directly downloaded from ENCODE. Funseq2 and CADD scores were directly calculated from their website. The list of highly prioritized variants discovered only by RADAR were provided in Supplementary Table S9. The comparison of RADAR baseline scores of HGMD vs 1kg variants were given in Figure S 10. Since the majority of 1kG variants are located far away from the exon regions, we further extracted variants that are only inside the RBP regulome for both HGMD and 1kG variants and compared their RADAR baseline scores.






### 7 Applying RADAR to somatic variants in cancer

The breast, liver, lung, and prostate cancer variants were downloaded from the paper by *Alexandrov et al[11]*. We first calculated the baseline RADAR scores on these four cancer types. We found that in most cancer types, COSMIC genes and recurrent RBP peaks are associated with more high impact variants. Results are shown in Figure S 11.





We also used expression profiles were downloaded from TCGA and the mutational variants as disease-specific features to prioritize breast cancer variants. Several more interesting examples from breast cancer were given in the following figures. We have listed the somatic variants that are only highlighted by RADAR in Supplementary Table S10 and Supplementary Table S11.





Figure S 12. Highlighted breast cancer somatic variants in 3'UTR region



# 8 Comparison of RADAR to other methods

Below we show the comparison of RADAR to FunSeq2 and also describe the relevance of each feature to variant prioritization on the RBP regulome.

| Universal Features                     | Same as FunSeq2? | Relevance to RADAR   |
|--|------------------|--|
| Cross-Population Conservation in eCLIP | Ν                | Conservation of post-transcriptional regulome              |
| Cross-Species Conservation             | Y                | Important for considering cross-species conservation.      |
| Structural Conservation (Evofold)      | Ν                | RNA secondary structure                                    |
| RBP Binding Hubs                       | Ν                | Binding hubs are more conserved                            |
| RBP-gene associations                  | Ν                | Gene expression changes caused by motif disruption         |
| Motif Disruption                       | Ν                | Disrupts binding of RBPs                                   |
| Tissue Specific Features               | Same as FunSeq2? | Relevance to RADAR   |
| <b>RBP</b> Regulatory Potential        | Ν                | RBPs regulate gene networks                                |
| Differential Expression of Key Genes   | Ν                | DE is a hallmark of regulation                             |
| Mutational Recurrence                  | Ν                | Recurrence in specific tissues demonstrate unique hotspots |

#### Table S 4 Comparison of RADAR to Funseq2


## 9 Using cell type specific information as validation

We used HepG2 and K562 specific data to build the RADAR model independently. Below are two examples illustrating the effect of cell type specific data on the RADAR score.

### 9.1 <u>Example 1: Comparison of full RADAR scores on variants in common and differentially</u> expressed genes in HepG2 and K562.

Here we show that somatic Liver cancer variants [11] falling in genes with both high expression in K562 and HepG2 (top 10% expression from total RNA-seq) demonstrate comparable scores when using matched cell type scoring schemes. Those variants falling in genes with high expression in HepG2 (top 10%) but low in K562 (FPKM<1) demonstrate scores that are much lower when using the K562 scoring scheme.






Example 2: scoring on somatic variants from tumor-specific and pancan driver genes

We compare the HepG2 and K562 scores for a set of Liver cancer variants available publicly from the Alexandrov et al paper [11] Here we observed that variants that fall in CTNNB1, a well-known cancer driver gene unique to liver cancer are scored much higher when using the HepG2 version of the score compared to the K562 version. As a control, we look at the scores of variants falling in TP53, a well-known cancer driver, but not specific to liver cancer. The results are shown in Figure S 14 below.





# 10 Downloading and Using the RADAR software

To better illustrate how RADAR works, we provided a simple flowchart of calculations for scoring a variant using RADAR in Figure S 15.



| Variant in RBP regulome?  | $\boxed{\begin{array}{c} \frac{n_{p}}{p_{p}+n_{c}} \\ \frac{n_{p}}{G(pc)} \times (1+p\log_{2}p+(1-p)\log_{2}(1-p)) \end{array}}_{G(pc)} + \boxed{\begin{array}{c} \frac{n_{p}}{p_{p}+n_{c}} \\ \frac{n_{p}}{G(pc)} \times (1+p\log_{2}p+(1-p)\log_{2}(1-p)) \end{array}}_{G(pc)} + \boxed{\begin{array}{c} \text{Gerp} \\ 0.62 \times \frac{1}{1+e^{-4\pi i_{p}(G(RP)-1B5)}} \end{array}}_{O \ if \ F, 1 \ if \ T \end{array}} + \boxed{\begin{array}{c} \text{Evolut} \\ 0 \ if \ F, 1 \ if \ T \end{array}}_{O \ if \ F, 1 \ if \ T \end{array}}$  |
|---------------------------|--|
| +                         |  |
| Breaks Motif?             | Entropy Based Motif Disruption<br>score       RBP-gene expression change<br>after knockdown <i>pscorex</i> (1+ <i>p</i> ) <i>og</i> <sub>2</sub> <i>p</i> +(1- <i>p</i> ) <i>og</i> <sub>2</sub> (1- <i>p</i> ))       Image: the second seco |
| +                         |  |
| Tissue Specific Included? | Mutational Recurrence<br>Binomial(n, p)RBP Regulatory Potential<br>$E = \beta_1 x + \beta_0$<br>0 or 1, based on p from $\beta_1$ Key Genes (Diff. Exp.) $p_{adj}$ from DESeq2<br>0 or 1, based on $p_{adj}$   |
| =<br>Final RADAR Score    |  |

We include a downloadable ZIP file at http://radar.gersteinlab.org/#!page-downloads which contains the RADAR source code (radar.py) and a directory containing all data files needed by RADAR (resources/). Individual files are listed below for download, and include descriptions of

each file. This website also provides software documentation, usage information, performance benchmarks, and test examples. We also provided a web version of the software that can be used to run RADAR directly through the site. A variant file (BED format) can be uploaded, with the option to select any tissue-specific features. The output contains each score feature as well as the full RADAR score.

RADAR can also be run from the command line after unzipping radar.zip and downloading the necessary dependencies (Python, BEDTools and pybedtools). Users can run the software using the following command:

```
python radar.py -b [BED file containing variants to be scored] -
o [output directory] -c [cancer type] [-kg -mr -rp]
```

The -kg, -mr and -rp are optional parameters that are used to indicate whether tissue-specific scores (key genes, mutation recurrence, and RBP regulation power) should be computed. These options require specifying a TCGA cancer abbreviation. After running the software, the output scores can be found in

[input BED file name].radar out.bed

The RADAR source code can be found at https://github.com/gersteinlab/RADAR. Included below is a step-by-step walkthrough of using RADAR to score the Alexandrov *et al* breast cancer variants.

```
[yf95@farnam1 ~]$ python
Python 2.7.13 (default, Jun 1 2017, 16:52:45)
[GCC 5.4.0] on linux2
Type "help", "copyright", "credits" or "license" for more information.
>>> import pybedtools
>>>
[[yf95@farnam1 ~]$ bedtools
bedtools is a powerful toolset for genome arithmetic.
           v2.27.1
Version:
About:
           developed in the quinlanlab.org and by many contributors worldwide.
           http://bedtools.readthedocs.io/
Docs:
Code:
           https://github.com/arg5x/bedtools2
Mail:
           https://groups.google.com/forum/#!forum/bedtools-discuss
Usage:
           bedtools <subcommand> [options]
```

Dependencies for RADAR include BEDTools (which can be found at http://bedtools.readthedocs.io/en/latest/content/installation.html), Python (which can be found at https://www.python.org/downloads/, our tests were conducted with version 2.7), and pybedtools (http://daler.github.io/pybedtools/main.html).

The RADAR package can be downloaded at http://radar.gersteinlab.org/#!page-downloads. The unzipped file includes a radar directory contains python executable script and a resources directory containing all data files needed by the RADAR script to produce scores. The example file (Breast.bed) is downloadable at http://radar.gersteinlab.org/#!page-example.

| [ <b>[yf95@</b> | farnam1 | example]\$ | head | Breast.bed |                              |
|-----------------|---------|------------|------|------------|------------------------------|
| chr1            | 13506   | 13507      | G    | Α          | TCGA-EW-A10Z-01A-11D-A142-09 |
| chr1            | 14841   | 14842      | G    | Т          | PD5935a                      |
| chr1            | 16995   | 16996      | Т    | С          | PD7201a                      |
| chr1            | 17764   | 17765      | G    | Α          | PD5935a                      |
| chr1            | 17764   | 17765      | G    | Α          | PD7216a                      |
| chr1            | 28587   | 28588      | G    | Т          | PD4962a                      |
| chr1            | 30527   | 30528      | С    | Т          | PD5935a                      |
| chr1            | 61396   | 61397      | G    | Α          | PD4967a                      |
| chr1            | 69522   | 69523      | G    | Т          | TCGA-BH-A0BP-01A-11D-A10Y-09 |
| chr1            | 83442   | 83443      | С    | Т          | PD4072a                      |

We run the software on the command line as follows:

```
python radar.py -b ../Breast.bed -o .. -c BRCA -kg -mr -rp
```

[[yf95@farnam1 radar]\$ python radar.py -b ../Breast.bed -o .. -c BRCA -kg -mr -rp [[yf95@farnam1 radar]\$ ls .. Breast.bed Breast.radar\_out.bed radar radar.zip

RADAR has generated the output file, Breast.radar\_out.bed, which contains the list of scored variants. A head of the output file is shown below (note that the header takes up one line in the file, but is broken onto two lines in this screenshot):

| [[yf95@farnam1 radar]\$ head/Breast.radar_out.bed |       |       |     |     |                             |          |         |        |      |   |          |       |           |           |     |                |        |
|---|-------|-------|-----|-----|-----------------------------|----------|---------|--------|------|---|----------|-------|-----------|-----------|-----|----------------|--------|
| chr   | start | stop  | ref | alt | cross                       | _species | _conser | vation | RBP_ | binding_  | hub GERP | Evofo | old motif | f_disrupt | ion | RBP_gene_assoc | iation |
| total_universal key_genes                         |       |       |     |     | mutation_recurrence RBP_reg |          |         |        |      | ulation_power total_tissue_specific total_score |          |       |           |           |     |                |        |
| chr1  | 13506 | 13507 | G   | Α   | 0                           | 0        | 0       | 0      | 0    | 0   | 0        | 0     | 0         | 0         | 0   | 0              |        |
| chr1  | 14841 | 14842 | G   | т   | 0                           | 0        | 0       | 0      | 0    | 0   | 0        | 0     | 0         | 0         | 0   | 0              |        |
| chr1  | 16995 | 16996 | Т   | С   | 0                           | 0        | 0       | 0      | 0    | 0   | 0        | 0     | 0         | 0         | 0   | 0              |        |
| chr1  | 17764 | 17765 | G   | Α   | 0                           | 0        | 0       | 0      | 0    | 0   | 0        | 0     | 0         | 0         | 0   | 0              |        |
| chr1  | 28587 | 28588 | G   | т   | 0                           | 0        | 0       | 0      | 0    | 0   | 0        | 0     | 0         | 0         | 0   | 0              |        |
| chr1  | 30527 | 30528 | С   | т   | 0                           | 0        | 0       | 0      | 0    | 0   | 0        | 0     | 0         | 0         | 0   | 0              |        |
| chr1  | 61396 | 61397 | G   | Α   | 0                           | 0        | 0       | 0      | 0    | 0   | 0        | 0     | 0         | 0         | 0   | 0              |        |
| chr1  | 69522 | 69523 | G   | т   | 0                           | 0        | 0       | 0      | 0    | 0   | 0        | 0     | 0         | 0         | 0   | 0              |        |
| chr1  | 83442 | 83443 | _ C | т   | 0                           | 0        | 0       | 0      | 0    | 0   | 0        | 0     | 0         | 0         | 0   | 0              |        |

### References

- 1. Lovci MT, Ghanem D, Marr H, Arnold J, Gee S, Parra M, Liang TY, Stark TJ, Gehman LT, Hoon S, et al: **Rbfox proteins regulate alternative mRNA splicing through** evolutionarily conserved **RNA bridges**. *Nat Struct Mol Biol* 2013, **20**:1434-1442.
- 2. Ye J, Beetz N, O'Keeffe S, Tapia JC, Macpherson L, Chen WV, Bassel-Duby R, Olson EN, Maniatis T: hnRNP U protein is required for normal pre-mRNA splicing and postnatal heart development and function. *Proc Natl Acad Sci U S A* 2015, 112:E3020-3029.
- van Roon AM, Oubridge C, Obayashi E, Sposito B, Newman AJ, Seraphin B, Nagai K: Crystal structure of U2 snRNP SF3b components: Hsh49p in complex with Cus1pbinding domain. RNA 2017, 23:968-981.

- 4. Lin PC, Xu RM: Structure and assembly of the SF3a splicing factor complex of U2 snRNP. *EMBO J* 2012, 31:1579-1590.
- 5. Obeng EA, Ebert BL: Charting the "Splice" Routes to MDS. Cancer Cell 2015, 27:607-609.
- 6. Rousseau F, Labelle Y, Bussieres J, Lindsay C: The fragile x mental retardation syndrome 20 years after the FMR1 gene discovery: an expanding universe of knowledge. *Clin Biochem Rev* 2011, **32**:135-162.
- 7. Crawford DC, Acuna JM, Sherman SL: **FMR1 and the fragile X syndrome: human** genome epidemiology review. *Genet Med* 2001, **3**:359-371.
- 8. Lambert N, Robertson A, Jangi M, McGeary S, Sharp PA, Burge CB: **RNA Bind-n-Seq:** quantitative assessment of the sequence and structural binding specificity of RNA binding proteins. *Mol Cell* 2014, **54**:887-900.
- 9. Bailey TL: DREME: motif discovery in transcription factor ChIP-seq data. *Bioinformatics* 2011, 27:1653-1659.
- 10. Love MI, Huber W, Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014, **15**:550.
- 11. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, et al: **Signatures of mutational processes in human cancer.** *Nature* 2013, **500**:415-421.